NovoCure Limited Ordinary Shares (NVCR) is a publicly traded Healthcare sector company. As of September 9, 2026, NVCR trades at $16.88 with a market cap of $2.09B and a P/E ratio of -12.98. NVCR moved +0.18% today. Year to date, NVCR is +30.32%; over the trailing twelve months it is +33.73%. Its 52-week range spans $9.82 to $27.47. Analyst consensus is buy with an average price target of $29.50. Rallies surfaces NVCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for NVCR, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $16.88 |
| Market Cap | $2.09B |
| P/E Ratio | -12.98 |
| EPS | $-1.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.47 |
| 52-Week Low | $9.82 |
| Volume | 133 |
| Avg Volume | 0 |
| Revenue (TTM) | $699.19M |
| Net Income | $-148.56M |
| Gross Margin | 76.13% |
4 analysts cover NVCR: 0 strong buy, 2 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $29.50.